The Comprehensive in vitro Proarrhythmic Assay (CiPA) is a series of assays designed to predict arrhythmias and not simply QT prolongation.
Nova staff have provided the manual ion channel data for the FDA which has been used to parameterize the in silico action potential model and provide a benchmark for the ILSI/HESI automated patch clamp study.
With our experienced staff, we can fulfill all of the CiPA recommendations.
With our QT Fingerprinting™ methodology, we can predict the amount of QT prolongation your compound may be associated with in humans…preclinically.
This method doesn’t simply categorize compounds as having low or high risk of some level of QT prolongation, but can actually assign a predicted amount of QT change which may occur at various tested concentrations.
Comparison of predicted vs measured QTc change using QT Fingerprinting™
Determine Clinical QT Risk Early in Development
How do you currently interpret ion channel data? Pick arbitrary levels of block…rank order
compounds…rely just on the degree of hERG block? With QT Fingerprinting, you no
longer need to guess what a 25% block of hERG, 20% block of Cav1.2, and 15% block
of late Nav1.5 mean. Using ion channel data from those 3 currents, the QT Fingerprinting
algorithm can predict the QT change in milliseconds of your compounds.
The model has a high degree of specificity and selectivity in predicting whether a
compound will pass or fail a TQT test.
QT Fingerprinting can also be used to predict the QT/PK profile
of your compounds.